Aidy

Most IBD patients make the same mistake when a flare starts. They cancel the gym, stay home, and wait it out. It makes sense. Fatigue, urgency, and pain are real. But complete inactivity during a flare leads to muscle loss, worsened mood, and a harder recovery once things stabilize. Research links prolonged inactivity in IBD patients to higher rates of depression and anxiety, which compounds the psychological toll the flare is already taking. The problem is that the opposite approach, pushing through your normal routine, carries genuine physiological risk too. Strenuous exercise can redirect up to 80% of blood flow away from your digestive tract, worsening the exact symptoms you're trying to manage. So the question every IBD patient faces during a flare is: where's the middle ground? And the answer depends on flare severity in ways most "exercise with IBD" articles never specify. We wrote a practical framework for adjusting exercise during mild, moderate, and severe flares, including when to scale back, when to pause entirely, and how to return to your routine safely afterward. Link in the comments.

Most people with IBD have been told to track their symptoms at some point, and most have also wondered whether it actually makes a difference. You already take medications, see your gastroenterologist, and manage flares as they come. Adding a daily logging habit feels like homework with no clear payoff. The clinical research suggests the payoff is real, but not in the way most people expect. Symptom tracking will not put you into remission. No app replaces your medications or your GI team. The benefits show up in a different place entirely: the gap between your appointments, where flares escalate, side effects go unreported, and patterns that matter clinically get lost to memory. One randomized trial demonstrated that patients using a real-time monitoring tool had a median flare duration of 18 days, compared to 77 days in the standard care group. The mechanism was straightforward. Tracking meant flares were caught early and treated immediately, rather than waiting for the next scheduled visit. But the evidence also has clear limits. Up to 54% of IBD patients have active inflammation while reporting no symptoms at all. What you feel and what is happening inside your gut are not always the same thing, and that disconnect has implications for how much weight a symptom diary should carry. We wrote about where the evidence is strong, where it falls short, and what specific benefits the clinical trials have consistently demonstrated. Link in comments.

A younger patient with IBD symptoms typically gets a diagnosis within two years. For patients over 50, the average wait is six years. That gap exists because IBD symptoms overlap heavily with conditions more common later in life. Diverticular disease, ischemic colitis, medication side effects. Doctors reasonably pursue those first, and up to 60% of elderly patients with IBD are initially misdiagnosed. The disease itself behaves differently after 50. Crohn's tends to be purely colonic in about 65% of older patients, which makes it look even more like other large intestine conditions. The presentation is often atypical: constipation instead of diarrhea, low-grade fever, general malaise. When symptoms break from the textbook, even experienced gastroenterologists can be steered toward other explanations. Treatment gets more complicated as well. The natural decline of immune function with age means that adding immunosuppressive medications creates compounded infection risk. And with older IBD patients taking an average of nine routine medications, drug interactions become a real concern in nearly three-quarters of cases. We wrote about what changes with diagnosis and treatment after 50, including how newer biologics may offer a better safety balance and what to bring to your GI appointment to speed up the process. Link in comments.

Social media is rife with posts about IBD supplements that aren't evidence-based. That's in part why so many people with Inflammatory Bowel Disease end up confused about supplements. Vitamin D, curcumin, omega-3s, probiotics. The recommendations are everywhere, but the actual clinical evidence behind each one varies enormously. Some of the findings are worth knowing. Vitamin D supplementation was associated with a 34% reduction in IBD-related ER visits and a 53% reduction in hospitalizations in a 2025 real-world study. Curcumin has earned a cautious nod from European gastroenterology organizations for mild to moderate ulcerative colitis, though the evidence for Crohn's remains too thin. The high-concentration probiotic VSL#3 achieved remission in 43.8% of UC patients versus 24.8% on placebo in randomized trials. Meanwhile, omega-3s show modest promise for reducing relapse risk, but guidelines still stop short of recommending them. The pattern across all of these: condition matters, strain matters, dosing matters. A generic probiotic from the supplement aisle is unlikely to contain the strains or concentrations used in the clinical trials that showed benefit. Turmeric from your spice rack is not the same as a standardized curcumin extract. And more than half of IBD patients have nutritional deficiencies in iron, B12, folate, or zinc that need correction regardless of any anti-inflammatory goals. We broke down the research for each major supplement category, including what guidelines actually say, where the evidence is strong, and where it falls short. We'll link the full article in the comments.

Getting a denial letter for a biologic you need is one of the most stressful moments in managing IBD. And it happens more than most people realize. Over 15% of IBD patients on biologics face an initial prior authorization rejection. Those patients wait an average of 60 days longer for approval. During that delay, corticosteroid dependence can rise 14% and IBD-related healthcare visits often increase nearly 13%. Most denials can be overturned. The process starts with your denial letter, which is legally required to state the specific reason for rejection. That reason becomes the target of the entire appeal. The centerpiece is a strong letter of medical necessity from your gastroenterologist, including your full diagnosis, every treatment tried and why each failed, current lab and endoscopy findings, and peer-reviewed evidence supporting the prescribed biologic. One area where patients can make a direct impact: consistent symptom tracking. Documented disease activity over weeks or months gives your care team concrete evidence that strengthens the appeal and makes initial denials less likely. We wrote about the full appeal process, including your rights to internal and external review under the ACA, in the article linked in the comments below.